Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BRAF NP_004324.2:p.V600E Clear all
Terminated Phase 1 Interventional

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

NCT04044430
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
Interventions
Binimetinib, Encorafenib, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

NCT02281760
View directory record Official record
Conditions
BRAF V600E Mutation
Interventions
Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 2 Interventional

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

NCT04061980
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
Interventions
Binimetinib, Encorafenib, Nivolumab
Drug · Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

NCT06902376
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Interventions
Cemiplimab, XL092
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

NCT01597908
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Vemurafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

NCT02196181
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
753
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 465 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

NCT01107418
View directory record Official record
Conditions
Malignant Melanoma
Interventions
RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

NCT04017650
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Suspended Phase 1 Interventional

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

NCT06102902
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Cetuximab, Computed Tomography, Echocardiography Test, Encorafenib, Magnetic Resonance Imaging, Multigated Acquisition Scan
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062
View directory record Official record
Conditions
Melanoma
Interventions
GSK1120212, Chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

NCT03224767
View directory record Official record
Conditions
BRAF V600E Mutation Present, Papillary Craniopharyngioma
Interventions
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
106
States / cities
Birmingham, Alabama • Auburn, California • Berkeley, California + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 1 Interventional Results available

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225
View directory record Official record
Conditions
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 1 Interventional

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160
View directory record Official record
Conditions
BRAF V600 Colorectal Cancer
Interventions
Dabrafenib, LTT462, Trametinib, LXH254, TNO155, Spartalizumab, Tislelizumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

NCT04657991
View directory record Official record
Conditions
Melanoma
Interventions
Encorafenib, Binimetinib, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Orlando, Florida • Fairway, Kansas • Overland Park, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Early Phase 1 Interventional

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

NCT06610682
View directory record Official record
Conditions
BRAF V600E Mutation
Interventions
Plixorafenib, Retifanlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Results available

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

NCT04390243
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Binimetinib, Encorafenib
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945
View directory record Official record
Conditions
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cetuximab, Irinotecan, Panitumumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 22, 2026, 12:56 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

NCT02143050
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Metformin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 22, 2026, 12:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC)
Interventions
Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 12:56 AM EDT
Terminated Phase 1 Interventional

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

NCT05743036
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
ZN-c3, Encorafenib, Cetuximab
Drug
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Merriam, Kansas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 22, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

NCT03975231
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Interventions
Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib
Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Duarte, California • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 12:56 AM EDT